溢多利(300381) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥202,399,201.05, representing a 1.79% increase compared to ¥198,841,582.87 in the same period last year[5] - Net profit attributable to shareholders decreased by 75.19% to ¥4,870,526.10 from ¥19,630,209.75 year-on-year[5] - Basic and diluted earnings per share fell by 75.31% to ¥0.0099 from ¥0.0401 in the same period last year[5] - Net profit for the current period was ¥5,044,416.75, a decrease of 74.8% from ¥20,038,353.72 in the previous period[23] - The profit attributable to the parent company's shareholders was ¥4,870,526.10, down from ¥19,630,209.75, indicating a decline of 75.8%[23] - The total comprehensive income for the current period was ¥5,679,501.27, down from ¥17,191,761.29, a decrease of 66.9%[23] Cash Flow - The net cash flow from operating activities was -¥24,751,394.41, a decline of 146.70% compared to ¥52,995,539.37 in the previous year[5] - Cash inflow from operating activities totaled 205,286,219.50, a decrease of 16% compared to 244,444,481.49 in the previous period[24] - Net cash outflow from operating activities was -24,751,394.41, contrasting with a positive cash flow of 52,995,539.37 in the previous period[24] - Cash inflow from investment activities was 290,759,389.61, an increase of 11.8% from 260,060,152.19 in the previous period[25] - Net cash flow from investment activities was 44,915,743.56, recovering from a negative cash flow of -138,031,352.97 in the previous period[25] - The net increase in cash and cash equivalents was ¥24,214,405.11, a decrease of 56.92% compared to the previous year[12] - Total cash and cash equivalents at the end of the period reached 337,520,876.62, up from 308,277,166.79 in the previous period, reflecting an increase of 9.4%[25] - The impact of exchange rate changes on cash and cash equivalents was 261,805.99, compared to -3,563,363.18 in the previous period, indicating a positive shift[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,891,375,591.82, down 1.94% from ¥2,948,587,167.07 at the end of the previous year[5] - Total liabilities decreased to ¥230,027,116.88 from ¥294,388,193.40, a decline of approximately 21.9%[20] - The total equity attributable to the parent company was ¥2,617,017,580.27, slightly up from ¥2,611,511,969.65[20] - The total current assets decreased to 1,231,875,161.02 RMB from 1,283,485,205.88 RMB[18] - The total non-current assets include fixed assets valued at 873,517,025.03 RMB, down from 903,041,179.58 RMB[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,922, with no preferred shareholders having restored voting rights[13] - Zhuhai Jindadi Investment Co., Ltd. holds 29.01% of shares, amounting to 142,458,378 shares, with 37,500,000 shares pledged[13] - The number of unrestricted shares held by the top ten shareholders totals 142,458,378 shares[13] - The company has 10,887,600 shares held in the stock repurchase account[14] Investments and Projects - A total investment of 230 million RMB has been allocated for the Yiduoli Innovation Park project, focusing on biotechnology research and development[16] - The company plans to grant 6.38 million restricted stocks under the 2025 incentive plan, with an initial grant price of 3.73 RMB per share[15] Financial Expenses and Income - The company reported a 39.32% increase in financial expenses, amounting to an increase of ¥1,690,617.67 due to reduced interest income[10] - Investment income rose by 129.57% to an increase of ¥1,842,639.06, attributed to previous losses from joint ventures and newly purchased financial products[10] Research and Development - Research and development expenses were ¥22,685,597.45, compared to ¥22,000,561.50 in the previous period, reflecting an increase of 3.1%[22] Other Financial Metrics - Other comprehensive income after tax for the current period was ¥635,084.52, compared to a loss of ¥2,846,592.43 in the previous period[23] - Total operating costs amounted to ¥192,304,232.25, up from ¥185,606,812.47, reflecting a rise of approximately 3.7%[22] - The weighted average return on net assets decreased to 0.19% from 0.75% year-on-year[5] Board and Audit - The company has not yet audited its first-quarter report for the current year[26] - The board of directors of Guangdong Yiduoli Biotechnology Co., Ltd. convened on April 23, 2025, to discuss financial matters[27]